GSTP1 and prostate carcinoma: Detection of GSTP1 methylation in all types of body fluids of prostate cancer patients represents a promising epigenetic biomarker, which is already under evaluation for the application of new prognostic methods (Cairns et al., 2001; Esteller, 2008; Yang and Park, 2012; Figure 2).